Showing results (431-440 of 520) with videos related to
Sort By:
Pageof 52
Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.Oncotarget|October 8, 2016
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphomaAtish Mohanty, Natalie Sandoval, Manasi Das, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Novel antineoplastic agents with efficacy against multidrug resistant tumor cellsJ C Medina, B Shan, H Beckmann, et al.JCI Insight|July 10, 2023
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphomaZhen Han, Xiwei Wu, Hanjun Qin, et al.Journal for Immunotherapy of Cancer|March 23, 2021
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancerXu Cao, Bolei Li, Jing Chen, et al.Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|November 2, 2021
Evaluation of classic and novel ultrasound signs of placenta accreta spectrumD W Skupski, C M Duzyj, J Scholl, et al.Cancer|October 28, 2023
A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokineticsVinod Pullarkat, Lisa S Chen, Joycelynne Palmer, et al.Clinical Lymphoma, Myeloma & Leukemia|July 23, 2024
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin LymphomaSwetha Kambhampati Thiruvengadam, Matthew G Mei, Lu Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancerWilliam K Oh, Philip W Kantoff, Vivian Weinberg, et al.Proceedings of the National Academy of Sciences of the United States of America|May 13, 1999
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumorsB Shan, J C Medina, E Santha, et al.Pageof 52